On this page

• The word “peptide” is doing too much work
• Three legal statuses, not one
• What the FDA’s categories actually mean
• What actually changed in 2026
• What a PCAC vote does, and does not, do
• “FDA approved peptides” is not a list the FDA keeps
• The “research use only” label is not a loophole
• What compounding is actually for
• What makes a specific peptide compoundable in the US
• Where each peptide stands, as at 8 September 2026
• What a valid prescription requires
• How to vet a compounding pharmacy on this
• What this means if you are thinking of offering peptides
• Where we sit, and what we do not offer

Are peptides legal in the US?

Some are, some are not, and the honest answer depends on which peptide and what you mean by legal. A few are FDA-approved drugs. A few more can lawfully be compounded and prescribed: sermorelin, the one peptide in our own programs, is in that group, and a licensed pharmacy can compound it today on a valid prescription. Many of the peptides sold online as “research use only” are in neither group, and a favourable FDA advisory vote in July 2026 did not change what any pharmacy may lawfully compound.

The word “peptide” is doing too much work

A peptide is just a short chain of amino acids. That is a chemistry description, not a legal category, and it covers things with wildly different legal status.

Semaglutide is a peptide. So is insulin. So is BPC-157. The first two are approved drugs with decades of regulatory history between them. The third is an unapproved substance that has never completed a human trial for any indication. Asking whether “peptides” are legal is like asking whether “tablets” are legal.

So the question has to be asked one substance at a time, and the useful version is: what is the legal status of this peptide, for this use, sold by this route.

Three legal statuses, not one

Almost every peptide in circulation sits in one of three places.

Approved drugs. The FDA has reviewed the evidence and approved the product for specific indications. Semaglutide, tirzepatide, liraglutide, teriparatide, octreotide and leuprolide are all peptides in this group. They are prescription medicines, lawful to prescribe and dispense through the normal channels, and their labels state what they are approved for.

Lawfully compoundable. Not approved as finished drugs, but permitted as bulk substances a licensed pharmacy can compound into a preparation for an individual patient with a valid prescription. This is a narrower group than the internet suggests, and which substances qualify is the subject of the rest of this article.

Neither. Sold online as “research use only” or “not for human consumption”, frequently with a disclaimer at the bottom of the page and dosing instructions further up it. These cannot lawfully be marketed for human use, and the disclaimer does not change that.

The commercial pressure sits almost entirely on the third group, because it is the cheapest to enter and the least policed.

What the FDA’s categories actually mean

If you have read anything about peptide legality you have met the phrase “Category 2”. Here is what the categories are, in the FDA’s own words.

When a substance is nominated for the 503A bulks list, the list of bulk drug substances that compounding pharmacies may use, the FDA sorted nominations into three categories:

Category 1. Substances “nominated with sufficient supporting information for FDA to evaluate them” that do not appear on another list. For these, the FDA “does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met.”

Category 2. Substances where the FDA “has identified significant safety risks relating to the use of these substances in compounding pending further evaluation.” For these the agency “would consider taking action against a compounder.”

Category 3. Nominated “with insufficient supporting information for FDA to evaluate them.” Also exposed to enforcement action.

Two things people get wrong about this. Category 1 is not approval; it is an enforcement posture, a statement that the FDA does not currently intend to act. And as of 7 January 2025 the FDA stopped placing newly nominated substances into these categories at all, so the framework describes a fixed historical set rather than a live filing system.

Source: FDA, Bulk Drug Substances Used in Compounding Under Section 503A.

What actually changed in 2026

Two events, and the gap between what they were and how they were reported is the reason this page exists.

16 April 2026. The FDA published a Federal Register notice announcing two advisory committee meetings to review twelve peptide substances for possible inclusion on the 503A bulks list. All twelve had been placed in Category 2 in September 2023, the category the FDA associates with significant safety risks, so the notice moved them from a position where compounding drew enforcement attention to one where their eligibility would be examined. Seven were set for July 2026, five for a meeting before the end of February 2027. Roster and dates per Hyman, Phelps & McNamara’s FDA Law Blog, reading the Federal Register notice.

The important thing about that step, and the thing the marketing skipped: leaving Category 2 is not arriving anywhere. None of the twelve was ever in Category 1, so none had a lawful compounding basis before the move, and the move did not create one.

23 and 24 July 2026. The Pharmacy Compounding Advisory Committee met and voted on seven peptides. Six received a favourable recommendation for possible inclusion on the 503A bulks list, and one did not.

Tallies from The American Journal of Managed Care; meeting dates confirmed on the FDA’s own advisory committee calendar. Every one of those margins is narrow, which is worth noticing on its own.

A further five substances are reported as scheduled for review before the end of February 2027: cathelicidin LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF.

Within days the July vote was being marketed as FDA backing. It was not.

What a PCAC vote does, and does not, do

This is the part worth reading twice, because a great deal of product is currently being sold on a misunderstanding of it.

A Pharmacy Compounding Advisory Committee recommendation is advisory only. As the healthcare regulatory practice at Buchanan Ingersoll & Rooney puts it, the agency “retains responsibility for determining which substances ultimately appear on the 503A Bulks List, and FDA is not legally required to adopt” the committee’s recommendations. Their analysis is blunt about the effect: the votes “did not immediately make these peptides lawful for compounding.”

Before any of these six can lawfully be compounded, four things have to happen:

1. The FDA has to decide whether to accept the recommendation.
2. The FDA has to publish a proposed rule in the Federal Register.
3. A public comment period has to run.
4. The FDA has to publish a final rule actually adding the substance to the list.

There is no deadline on any of it. The last comparable process ran from a proposed rule in December 2016 to a final rule in February 2019, which is over two years.

A favourable vote also does not move a peptide into Category 1. Removal from Category 2 and a positive advisory recommendation are two steps on a path whose end is a rule that has not been written.

Source: Buchanan Ingersoll & Rooney, FDA Voted Yes on Six Peptides. Now What?. A critical policy view of the same vote was published in Health Affairs Forefront, arguing the compounding route risks functioning as a back door around the approval process.

”FDA approved peptides” is not a list the FDA keeps

People search for a list of FDA-approved peptides and vendors are happy to publish one. The premise is slightly wrong, and understanding why protects you.

The FDA approves drug products for indications. It does not maintain a category called “approved peptides”, so any list with that title is somebody’s editorial selection. The useful lists mix genuinely approved drugs with substances that are merely compoundable, and the less scrupulous ones fold in research chemicals so the page reads as reassurance.

You can check any substance yourself in about thirty seconds, and this is the single most useful habit in this whole subject:

1. Open Drugs@FDA, the agency’s database of approved drug products.
2. Search the active ingredient, not the brand or the street name.
3. If it returns an approved product, read what it is approved for. Approval for one indication is not approval for another.
4. If it returns nothing, it is not an approved drug product, whatever the seller’s page says.

If a vendor’s own literature cannot survive that check, that is the answer.

The “research use only” label is not a loophole

A large share of the peptide market runs on a specific piece of theatre. The product is sold labelled “for research use only” or “not for human consumption”, and the same site carries dosing protocols, injection guidance and before-and-after photographs.

The label does not create a lawful route to sell an unapproved drug for human use. It is a disclaimer attached to a product whose marketing contradicts it, and the contradiction is the evidence. Intended use is judged on the whole picture, not on the smallest text on the page.

For a business, the exposure is not theoretical and it is not limited to the seller. If you put your brand on it, market it, or make a claim about what it does, you are part of the marketing that establishes intended use.

What compounding is actually for

Understanding this makes the rest of the subject obvious, and most people offering peptides have never had it explained.

Section 503A exists so a licensed pharmacist can prepare a medication for an individual patient with an individual need that an approved product does not meet. A patient who cannot tolerate a dye in the commercial tablet. A child who needs a liquid where only capsules exist. A dose that is not manufactured.

It is a clinical exception, not a manufacturing route. The FDA is explicit on the central condition: a drug product “must be compounded for an identified individual patient based on the receipt of a valid prescription order” (FDA guidance on the section 503A prescription requirement). The bulks list exists alongside that, because compounding from raw substances that have never been through approval is the part that needed policing.

Worth separating from 503A entirely: a 503B outsourcing facility is a different category, created in 2013 by the Drug Quality and Security Act. Those facilities register with the FDA, are inspected by the FDA on a risk-based schedule, and are subject to current good manufacturing practice requirements that 503A pharmacies are not. If a supplier is vague about which one you are buying under, that is the first thing to pin down.

Read that way, the peptide question answers itself. A business planning to offer the same peptide to hundreds of clients as a branded programme is not describing an individual clinical need that an approved product cannot meet. It is describing a product line. The compounding pathway can carry it when the substance qualifies and each prescription is genuine, and it was never designed as a route to market for substances that could not get approved on their own evidence.

That is the concern the Health Affairs Forefront piece raises about the July vote, and it is the reason the rulemaking that follows an advisory recommendation is slow rather than quick.

What makes a specific peptide compoundable in the US

Compounding is where the lawful supply of a non-approved peptide actually happens in this country, so it is worth knowing the test a pharmacy has to satisfy. It is narrower and more mechanical than the marketing around it suggests, and it is the reason the table below reads the way it does.

Under section 503A, a bulk drug substance qualifies on one of three bases. In the FDA’s own wording, bulk drug substances must:

• “Comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph if one exists, and the USP chapter on pharmacy compounding”
• Or be “components of FDA-approved drug products if an applicable USP or NF monograph does not exist”
• Or “appear on FDA’s list of bulk drug substances that can be used in compounding (the 503A bulks list) if such a monograph does not exist and the substance is not a component of an FDA-approved drug product”

Two further conditions apply to every substance whichever basis it uses. It must “have been manufactured by an establishment registered with FDA under section 510 of the FD&C Act”, and it must be “accompanied by a valid certificate of analysis” (FDA, Bulk Drug Substances Used in Compounding Under Section 503A).

That is the whole test, and it settles most of the argument without a legal opinion. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon have no USP monograph. None is a component of an approved drug product. None is on the 503A bulks list. There is no fourth door in the statute.

Worth being precise about what that means, because the loose version of it is wrong in both directions. A pharmacy compounding one of those substances today is not defying a prohibition aimed at it by name. It is working without an affirmative basis. That distinction changes nothing about the inspection risk, but it is the reason this area can move quickly once a rule is written, and the reason “the FDA has not said we can’t” is a sentence you will hear from suppliers who are describing an absence rather than a permission.

Category 1 is the exception that explains sermorelin, and it is not a fourth basis in the statute. It is a published enforcement posture: the FDA has said it does not intend to take action against a compounder using a Category 1 substance while evaluation continues, subject to the conditions in its guidance. Sermorelin also carries something the other six do not, which is a history as an approved finished drug that the FDA has formally determined was not withdrawn for safety or effectiveness reasons.

The ingredient is a separate question from the substance

Two requirements catch out businesses that have satisfied themselves on the substance and stopped there.

Research-grade material cannot be used for human compounding. An active ingredient labelled “research use only” is ineligible whatever purity the supplier claims. The Alliance for Pharmacy Compounding’s briefing for prescribers is direct about it: research-grade peptides are not appropriate for human use, and a pharmacy sourcing from that channel has a problem that is independent of which peptide it happens to be making.

The supplier has to be FDA-registered and produce a certificate of analysis. Both are documents, both are askable for, and neither is commercially sensitive. A supplier who cannot produce a section 510 registration and a valid certificate of analysis is not a borderline case, and the request itself is a useful filter.

The 40 amino acid line, which decides some of this before anything else does

There is a boundary most peptide marketing never mentions. A peptide of 40 amino acids or fewer is regulated as a drug. Longer than that and it is a biological product, licensed under a different statute that a 503A pharmacy cannot operate under at all.

This is why a well-run compounding pharmacy will decline tesamorelin or hCG for reasons that have nothing to do with safety data, advisory votes or the bulks list. They are on the wrong side of the line, and no amount of prescription paperwork moves them across it. It is a fast disqualifier, it is worth asking about early, and a supplier who cannot tell you which side of it a product sits on has told you how much of this they have worked through.

Where each peptide stands, as at 8 September 2026

Iman asked for this table and it is the most useful thing on the page, so here is the caveat first and in plain sight: this is a snapshot dated 8 September 2026. This area moved twice in 2026 alone and it is due to move again before the end of February 2027. Check the date at the top of this section against today before you rely on any row, and confirm anything you intend to act on with your own pharmacy and your own counsel.

The right-hand column is the one that matters, and it says no twelve times. A favourable advisory recommendation and a place on the bulks list are not the same thing, and only the second one lets a pharmacy compound.

Semaglutide and tirzepatide are deliberately absent from this table. Both are approved drug products in their own right, and the separate question of when a compounded version of an approved drug may be prepared turns on different rules again.

What a valid prescription requires

If the substance is permitted, the prescription still has to be real. The parts that get skipped:

A patient-specific prescription. Under 503A the preparation is for a named individual, following a prescriber’s determination for that person. Bulk preparation for office stock is a different section of the statute with different rules.

A genuine prescriber relationship. Somebody licensed in the patient’s state has to evaluate them, and the evaluation has to precede the prescription. An intake form processed without clinical review is the failure mode that shows up in enforcement actions, and it is not cured by the form being long.

A clinical rationale that survives a look. Why this preparation, for this patient, rather than an approved product. Where an approved product exists and would work, reaching for a compounded one needs a reason on the record.

Documentation that exists before it is needed. The prescription, the evaluation, the rationale, the pharmacy’s own records. This is the same lesson as the good faith exam in aesthetics: the file either supports you or it does not, and it is assembled beforehand or not at all.

None of that is exotic. It is the ordinary practice of medicine, and it is the part a business plan tends to treat as an implementation detail.

How to vet a compounding pharmacy on this

Your pharmacy’s regulatory posture becomes yours the moment you put your brand on the output. Five questions, and the answers are more revealing than any certificate.

1. Which specific substances will you compound for us, and on what basis? You want the substance named and the basis stated: monograph, component of an approved drug, or bulks list. “We can do peptides” is not an answer.
2. Are you 503A or 503B, and which are we buying under? They are different regimes with different rules. A 503B outsourcing facility registers with the FDA and can prepare without patient-specific prescriptions; a 503A pharmacy cannot.
3. What is your position on the substances that got a favourable PCAC vote in July 2026? A pharmacy that is already compounding them is either seeing something you are not or taking a risk on your behalf. Ask which.
4. Show me your most recent inspection outcome. State board and, for a 503B, FDA. A reluctance here is the whole answer.
5. What happens to our patients if a substance we are using comes off the list? There is a right answer, which is a transition plan, and a wrong one, which is a shrug.

A pharmacy willing to compound anything you ask for is not being accommodating. It is telling you how it will behave when a regulator asks it a question about you.

What this means if you are thinking of offering peptides

The commercial case is obvious: clients ask for them, margins are good, and competitors are already advertising. The reasons to be careful are less obvious and they are worth stating plainly.

A recommendation is not a rule. If your supplier’s pitch rests on the July 2026 vote, the pitch rests on something that has no legal effect yet.

Disease and healing claims are the fastest way into trouble, independent of the substance’s status. “Supports tissue repair” and “heals your gut” are not the same sentence to a regulator.

Your pharmacy’s position is your position. Ask which specific substances they will compound, on what basis, and get it in writing. A pharmacy willing to compound anything is telling you something about its own compliance posture.

Enforcement has continued through the change. The advisory vote in July did not slow it down. Two more warning letters went out on 24 August 2026, and the theory in them applies to any seller whose marketing establishes an intended use for humans, disclaimer or not.

The rules are moving in both directions. Twelve substances came off Category 2 in April 2026 and six got a favourable advisory vote in July. Five more are due for review before the end of February 2027. Anything you build should survive the review going the other way.

Where we sit, and what we do not offer

We think the disclosure is more useful than a position statement, so here it is plainly.

The programs Local Healthcare operates include one peptide: sermorelin, a growth-hormone-releasing hormone analogue, prescribed where an independent clinician determines it is appropriate.

Sermorelin has a longer regulatory history than most of the substances in this article. It was approved as a finished drug under the brand GEREF, held by EMD Serono, and withdrawn from sale in 2008. In March 2013 the FDA published a formal determination that GEREF injection “was not withdrawn for reasons of safety or effectiveness”, the finding that permits abbreviated new drug applications for generic versions and that places the product in the Orange Book’s Discontinued Drug Product List rather than among withdrawals for cause (Federal Register, 4 March 2013). It sits in Category 1 on the 503A nominations, the category where the FDA has said it does not intend to take enforcement action against compounders.

Our other programs use approved drugs and their compounded equivalents: semaglutide and tirzepatide for weight management, where the compounding rules changed sharply in 2025 and are still moving, as we set out in does compounded semaglutide work, and is it going away; estradiol and micronized progesterone for menopause, and vitamin and metabolic support.

We do not currently offer BPC-157, TB-500, Semax, Epitalon, MOTS-c or KPV, and it is worth being accurate about why rather than hiding behind a compliance formula.

The FDA has not published a list naming those substances unlawful to sell. As of the 22 April 2026 update to its page on bulk substances that may present significant safety risks, they no longer appear in the active Category 2 table either. Anyone telling you the agency has expressly banned them by name is overstating it.

What is missing is the other half. None has a monograph, none is a component of an approved drug, and none is on the 503A bulks list, so there is no affirmative basis to compound one. And for direct sale outside compounding, the unapproved new drug provisions apply whether or not a substance is named on any list, which is the theory the FDA has actually been using: warning letters went to peptide sellers on 31 March, 17 June and, twice, 24 August 2026, the last pair a month after the favourable vote. Each rejects the research-use-only framing in near-identical language: “Despite statements on your product labeling marketing your products ‘for research use only’ and ‘not for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”

Those 2026 letters name other substances rather than the six from July, so nobody should read them as the specific answer on BPC-157. Read them as the answer on the theory. The position on the six is unsettled rather than expressly prohibited, and unsettled on the back of a narrow advisory recommendation is a poor foundation for a product line that would carry a partner’s brand as well as ours. We would rather revisit it when there is a final rule.

The partner sells the program to their client; Local Healthcare provides the platform and collects payment as the partner’s billing agent; the clinician is independent. Prescription treatments are provided only where an independent, licensed clinician determines they are clinically appropriate after reviewing a client’s health history, and not everyone qualifies. Compounded medications are prepared by state-licensed pharmacies, are not FDA approved, and no claim is made that they are as safe or effective as any branded alternative. Availability varies by state.

How current this is

Every regulatory fact on this page was checked against a primary source on 8 September 2026: the FDA for the compounding categories, the prescription requirement and the conditions a bulk substance must meet, the FDA’s advisory committee calendar for the July meeting, the Federal Register for the GEREF determination, the FDA’s own published warning letters for the enforcement dates, and The American Journal of Managed Care for the vote tallies. Where only industry publications carried a fact, the page says so in the sentence rather than presenting it as settled.

This article is general information about regulatory status. It is not legal advice, it is not medical advice, and it has not been reviewed by outside counsel. This area has moved twice already in 2026 and is scheduled to move again before the end of February 2027. Confirm anything you intend to rely on with your own counsel and your own pharmacy, and check the date above before treating any of it as current.